Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 23, Issue 9, Pages 1445-1457Publisher
WILEY
DOI: 10.1002/ejhf.2295
Keywords
Heart failure; CA125; MUC16
Categories
Funding
- CIBER Cardiovascular [16/11/00420, 16/11/00403]
- [PIE15/00013]
Ask authors/readers for more resources
CA125 is a reliable marker for congestion and inflammation in heart failure patients, strongly associated with a higher risk of adverse clinical events and potential for guiding decongestive therapy following acute heart failure events. Further research is needed to better understand its biological role and utility in clinical practice.
Congestion explains many of the signs and symptoms of acute heart failure (AHF) and disease progression. However, accurate quantification of congestion is challenging in daily practice. Antigen carbohydrate 125 (CA125) or mucin 16 (MUC16), a large glycoprotein synthesized by mesothelial cells, has emerged as a reliable proxy of congestion and inflammation in patients with heart failure (HF). In AHF syndromes, CA125 is strongly associated with right-sided HF parameters and a higher risk of adverse clinical events beyond standard prognostic factors, including natriuretic peptides. Furthermore, CA125 has the potential for both monitoring and guide HF treatment following a decompensated HF event. The wide availability of CA125 in most clinical laboratories, together with its standardized measurement and reduced cost, makes this marker attractive for routine use in decompensated HF. Further research is required to understand better its biological role and its promising utility as a tool to guide decongestive therapy in HF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available